CAR-T cell therapyInvestigationalInvestigational
Idecabtagene vicleucel
How it works
Genetically modifies T cells to recognize and destroy cancer cells, providing a sustained immune response.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 80% of patients achieved a complete response, with a median progression-free survival of approximately 6 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.